Gilead Sciences plans to quadruple CAR-T cancer treatment production and increase oncology revenue by 2026.
Gilead Sciences aims to quadruple its cell therapy cancer treatment production by 2026, with a focus on chimeric antigen receptor T-cell (CAR-T) treatments. The company anticipates oncology products to make up a third of its revenue by the end of the decade. It has reduced the median turnaround time for Yescarta to 14 days and plans to expand its healthcare center network to reach a broader patient base.
March 15, 2024
5 Articles